InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,713.64
(
1.70%
)
US TECH 100
19,293.20
(
2.31%
)
Dow Jones
42,025.19
(
1.26%
)
Brent Oil
74.32
(
2.68%
)
Bitcoin
63,060.55
(
2.25%
)

Replies to post #506774 on Billionaire Boys Club Member Forum (BBCMF)

Replies to #506774 on Billionaire Boys Club Member Forum (BBCMF)
icon url

mick

02/17/20 10:54 AM

#506776 RE: mick #506774

OTCMKTS:IPIX 361Why Is Innovation Pharmaceuticals (OTCMKTS:IPIX) Stock Rising?Innovation Pharmaceuticals (OTCMKTS:IPIX) is receiving a lot of investor attention lately. The stock has already jumped more than 72% year-to-date and recently... 4.

1KInvestors Fleeing CytoDyn Missing the Golden Nugget from the BLA DelaySell first analyze later mentality of investors oblivious to the increased likelihood of a BLA approval may cost them handsome upside CytoDyn...

OTCMKTS:BIEL 578Bioelectronics Corp (OTCMKTS:BIEL) Climbing Up The ChartsBioelectronics Corp (OTCMKTS:BIEL) has set the OTC Markets on fire after receiving U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain....
icon url

mick

02/18/20 10:40 AM

#506809 RE: mick #506774

OTCMKTS:IPIX 361Why Is Innovation Pharmaceuticals (OTCMKTS:IPIX) Stock Rising?Innovation Pharmaceuticals (OTCMKTS:IPIX) is receiving a lot of investor attention lately. The stock has already jumped more than 72% year-to-date and recently... 4.

1KInvestors Fleeing CytoDyn Missing the Golden Nugget from the BLA DelaySell first analyze later mentality of investors oblivious to the increased likelihood of a BLA approval may cost them handsome upside CytoDyn...

OTCMKTS:BIEL 578Bioelectronics Corp (OTCMKTS:BIEL) Climbing Up The ChartsBioelectronics Corp (OTCMKTS:BIEL) has set the OTC Markets on fire after receiving U.S. FDA Market Clearance for Over-The-Counter Treatment of Musculoskeletal Pain....
icon url

mick

02/19/20 12:35 PM

#506823 RE: mick #506774

MONMOUTH JUNCTION, N.J. and NORTH POINT, Hong Kong, Feb. 19, 2020 /PRNewswire/ -- CytoSorbents Corporation

(NASDAQ: CTSO), a critical care immunotherapy leader with more than 80,000 global treatments of its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients, and China Medical System Holdings Limited (CMS) (HKG:0867), a well-established, innovation-driven specialty pharma with a focus on sales and marketing in China and Asia, entered into an agreement to bring CytoSorb to mainland China to treat critically-ill patients with COVID-19 (fka Wuhan or 2019-nCoV) coronavirus infection.